SuperworthRoivant Sciences price to sales ratio ROIV
Market value divided by revenue over the last twelve months, since 2023.
- Today, Oct 23, 2026
- n/m
- a sliver of sales
- Last meaningful
- 103×
- Aug 2025
- 3-year median
- 75.9×
- 3-year range
- 52.3× to 146×
- Peer median
- 7.5×
Roivant Sciences' price to sales ratio is not a meaningful number today: a multiple this high rests on a sliver of sales.
It was last meaningful in Aug 2025, at 103×.
On the days it had one over the last 3 years, its median was 75.9×, from 52.3× in Aug 2024 to 146× in Jul 2023.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2025 | 103× | 61.6× | 103× |
| 2024 | 68.3× | 52.3× | 87.8× |
| 2023 | 87.5× | 69.9× | 146× |
Against its peers
Companies in Biotechnology nearest Roivant Sciences' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| ROIVRoivant Sciences | n/m |
| UTHRUnited Therapeutics | 8.0× |
| INCYIncyte | 4.0× |
| ALNYAlnylam Pharmaceuticals | 6.2× |
| ONCBeOne Medicines | 7.0× |
| EXELExelixis | 6.6× |
| NBIXNeurocrine Biosciences | 4.3× |
| HALOHalozyme Therapeutics | 8.6× |
| TECHBIO-TECHNE | 9.4× |
| RGENRepligen | 12.7× |
| KRYSKrystal Biotech | 20.9× |
| Peer median | 7.5× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Roivant Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.